Mats-Olof Wallin
Directeur Financier/CFO chez OxThera AB
Profil
Mats-Olof Wallin is currently the Chief Financial Officer & Deputy CEO at OxThera AB since 2020.
Prior to this, he worked as the CFO & Director-Investor Relations at Biotage AB from 2003 to 2012, the Chief Financial Officer at Karo Healthcare AB from 2018 to 2019, and the Chief Financial Officer & Senior Vice President at Swedish Orphan Biovitrum AB from 2013 to 2018.
He completed his undergraduate degree from the University of Uppsala.
Postes actifs de Mats-Olof Wallin
| Sociétés | Poste | Début |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Directeur Financier/CFO | 01/01/2020 |
Anciens postes connus de Mats-Olof Wallin
| Sociétés | Poste | Fin |
|---|---|---|
| KARO PHARMA AB (PUBL) | Directeur Financier/CFO | 01/10/2019 |
| SWEDISH ORPHAN BIOVITRUM AB | Directeur Financier/CFO | 20/07/2018 |
| BIOTAGE AB | Directeur Financier/CFO | 01/01/2012 |
Formation de Mats-Olof Wallin
| University of Uppsala | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOTAGE AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| KARO PHARMA AB (PUBL) | Health Technology |
| Entreprise privées | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
